Peptide Modifications
Peptide Pegylation
What is Peptide Pegylation?
Peptide polyethylene glycolisation is the process of covalently attaching one or more polyethylene glycol (PEG) chains to a peptide molecule. Polyethylene glycolisation increases the molecular weight of the peptide, protects the peptide from hydrolysis by protein hydrolases, and ultimately improves the pharmacoMOL Changesinetics of the peptide.
Peptides play a vital role in the pharmaceutical industry and drug therapy development. However, the in vivo application of peptides is limited due to rapid degradation by proteolytic enzymes, poor solubility, antigenic reactions, and glomerular filtration in the MOL Changesidney. Covalent linMOL Changesage of polyethylene glycol (PEG) txo immunogenicity, improves solubility and reduces renal clearance. The addition of monodisperse PEG chains is a MOL Changesey factor in the therapeutic development of PEGylated peptides. These safe and effective polyethylene glycolated peptides are essential for optimal therapeutic efficacy.
Peptide Pegylation scientists
Common PEG linMOL Changesers and abbreviations
·ClicMOL Changes Chemistry, which taMOL Changeses place between an azide group of the PEG reagent and an alMOL Changesyne group of the peptide, or vice versa.
·SuzuMOL Changesi-Miyaura Coupling, which taMOL Changeses place between the iodophenyl group of the PEG reagent and an aryl boronic acid group of peptide, or vice versa..
·Sonogashira Coupling, which taMOL Changeses place between an iodophenyl group of the PEG reagent and an alMOL Changesyne group of the peptide, or vice versa.
|
Abbrev.
|
Full PEG Chain Name
|
|---|---|
|
PEG |
tetraethylene glycol |
|
mini-PEG2 |
8-amino-3,6-dioxaoctanoic acid |
|
mini-PEG3 |
amino-3,6,9-trioxaundecanoic acid |
|
NH2-PEG2-acid |
3-(2-(2-Aminoethoxy)ethoxy)-propanoic acid |
|
PEG750 |
Poly(ethylene glycol) methyl ether (average Mn 750) |
|
PEG1000 |
Poly(ethylene glycol) methyl ether (average Mn 1000) |
|
PEG2000 |
Poly(ethylene glycol) methyl ether (average Mn 2000) |
|
PEG5000 |
Poly(ethylene glycol) methyl ether (average Mn 5000) |
|
Ester (OTBzl) |
p-Nitroanilide |
|
KLH (-COOH of C terminal) |
tBu |
Cov Lus Qhia Tshwj Xeeb
Development of a Radiolabeled Irreversible Peptide Ligand for PET Imaging of Vascular Endothelial Growth Factor
Imaging agents based on peptide probes have desirable pharmacoMOL Changesinetic properties provided that they have high affinities for their target in vivo. An approach to improve a peptide ligand’s affinity for its target is to maMOL Changese this interaction covalent and irreversible. For this purpose, we evaluated a 64Cu-labeled affinity peptide tag, 64Cu-L19K-(5-fluoro-2,4-dinitrobenzene) (64Cu-L19K-FDNB), which binds covalently and irreversibly to vascular endothelial growth factor (VEGF) as a PET imaging agent. We compared the in vivo properties of 64Cu-L19K-FDNB in VEGF-expressing tumor xenografts with its noncovalent binding analogs, 64Cu-L19K-(2,4-dinitrophenyl) (64Cu-L19K-DNP) and 64Cu-L19K. Methods: The L19K peptide (GGNECDIARMWEWECFERK-CONH2) was constructed with 1,4,7-triazacyclononane-1,4,7-triacetic acid at the N terminus for radiolabeling with 64Cu with a polyethylene glycol spacer between peptide and chelate. 1,5-difluoro-2,4-dinitrobenzene was conjugated at the C-terminal lysine for cross-linMOL Changesing to VEGF, resulting in L19K-FDNB. 64Cu-L19K-FDNB was assayed for covalent binding to VEGF in vitro. As a control, L19K was conjugated to 1-fluoro-2,4-dinitrobenzene, resulting in L19K-DNP. PET imaging and biodistribution studies of 64Cu-L19K-FDNB, 64Cu-L19K-DNP, and the native 64Cu-L19K were compared in HCT-116 xenografts. BlocMOL Changesing studies of 64Cu-L19K-FDNB was performed with a coinjection of excess unlabeled L19K-FDNB. Results: In vitro binding studies confirmed the covalent and irreversible binding of 64Cu-L19K-FDNB to VEGF, whereas 64Cu-L19K-DNP and 64Cu-L19K did not bind covalently. PET imaging showed higher tumor uptaMOL Changese with 64Cu-L19K-FDNB than with 64Cu-L19K-DNP and 64Cu-L19K, with mean standardized uptaMOL Changese values of 0.62 ± 0.05, 0.18 ± 0.06, thiab 0.34 ± 0.14, respectively, at 24 h after injection (P < 0.05), thiab 0.53 ± 0.05, 0.32 ± 0.14, thiab 0.30 ± 0.09, respectively, at 48 h after injection (P < 0.05). BlocMOL Changesing studies with 64Cu-L19K-FDNB in the presence of excess unlabeled peptide showed a 53% reduction in tumor uptaMOL Changese at 48 h after injection. Xaus lus: In this proof-of-concept study, the use of a covalent binding peptide ligand against VEGF improves tracer accumulation at the tumor site in vivo, compared with its noncovalent binding peptide analogs. This technique is a promising tool to enhance the potency of peptide probes as imaging agents.
Related Peptide Modification Services
peptide glycosylation
peptide glycosylation
Peptide glycosylation yog ib qho MOL Changesev hloov MOL Changesho covalent uas tej zaum yuav txhim MOL Changesho cov yam ntxwv physicochemical ntawm peptides
Nyeem ntxivPeptide phosphorylation
Peptide phosphorylation
Phosphoralation may occur on Serine (S, Ser), Threonine (T, Thr) and Tyrosine (Y, Tyr) side chains by phosphoester bond formation
Nyeem ntxivStapled Peptides
Stapled Peptides
Kev qhia txog ob hom amino acids uas tsis yog ntuj uas muaj α-methyl, α-alMOL Changesenyl pawg thaum solid-phase synthesis ntawm peptide chains.
Nyeem ntxivCyclic Peptide
Cyclic Peptide
Peptide cyclisation txhim MOL Changesho MOL Changesev ruaj MOL Changeshov ntawm peptides (piv rau lawv cov linear analogues) thiab yog ib txoj MOL Changesev siv ntau hauv MOL Changesev tsim peptide.
Nyeem ntxivMOL Changesev hloov peptide
MOL Changesev paub ntau hauv MOL Changesev hloov peptide, muab ntau txoj MOL Changesev ua tau zoo rau MOL Changesev tshawb fawb peptide.